Bone Health Technologies (BHT), a leading healthtech startup focused on non-pharmacological solutions for improving bone health and preventing fractures, has announced the opening of pre-orders for Osteoboost, the first FDA-cleared prescription wearable device for postmenopausal women with osteopenia. Osteoboost delivers targeted vibration therapy to the hips and spine, areas most at risk of osteoporotic fractures. Its patented combination of frequency and amplitude has been clinically proven to reduce spinal bone density loss by 85% and bone strength loss by 83%.
This innovative device, cleared by the FDA, is clinically validated to significantly slow bone density and strength loss through precision vibration therapy, emulating the bone-stimulating effects of high-impact exercise. Designed for convenience, Osteoboost is lightweight and wearable, allowing users to manage bone health during everyday activities like walking or household chores. Patients in clinical trials reported comfort, with some likening the experience to a massage.
Osteoboost’s effectiveness is backed by a pivotal clinical trial at the University of Nebraska Medical Center, which showed its ability to slow bone loss in the spine. Developed by Michael Jaasma, PhD, Chief Scientific Officer at BHT, whose research focused on mechanical loading effects on bone cells, the device is poised to make a significant impact in bone health management.
With high demand, the initial Founder’s Program for Osteoboost sold out quickly, and the company is speeding up production to fulfill pre-orders within 60-90 days. CEO Laura Yecies emphasized the device’s role in offering a safe, convenient, and non-invasive solution to protect bone density and prevent fractures. This milestone marks years of research and development, setting a new standard in bone health management.
Click here to read the original news story.